Thursday, June 6, 2013

Pfizer initiates Phase 1 trial for its biosimilar version of Humira

The Phase 1 trial will enroll 210 healthy volunteers in 3 arms - PF-06410293,  adalimumab (United States) or adalimumab (European Union).  This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of single subcutaneous dose of PF-06410293 and the licensed adalimumab products. The study is expected to complete in January 2014.

Enter your email address:


Delivered by FeedBurner